Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Encompass Health (NYSE:EHC) and its peers.
Although the S&P 500 is down 6.9% over the past six months, U.S. Physical Therapy’s stock price has fallen further to $70.65, losing shareholders 14.1% of their capital. This might have investors contemplating their next move.
Let’s dig into the relative performance of DaVita (NYSE:DVA) and its peers as we unravel the now-completed Q4 outpatient & specialty care earnings season.
Looking back on outpatient & specialty care stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including U.S. Physical Therapy (NYSE:USPH) and its peers.
Outpatient physical therapy provider U.S. Physical Therapy (NYSE:USPH) will be announcing earnings results tomorrow after market close. Here’s what investors should know.
JMP Securities initiates U.S. Physical Therapy (USPH) coverage with a $113 target, citing growth driven by acquisitions, partnerships, and strategic focus.
Concentra, a subsidiary of select medical, recently priced its IPO at $23.50 per share. Concentra offers occupational health services with 547 centers in 41 states.
